Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/-Negative Early Breast Cancer

Is the efficacy benefit of ribociclib sustained beyond the planned 3-year treatment duration for patients with hormone receptor–positive/(formerly )-negative early breast cancer in the NATALEE randomized clinical trial?In this exploratory 4-year analysis of 5101 patients from the NATALEE trial, ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) continued to demonstrate an invasive disease-free survival and distant disease-free survival benefit over NSAI alone by reducing the disease recurrence risk by 28.5%. The absolute iDFS benefit continued to increase from 3 to 4 years.NATALEE results continue to support the benefit of adding 3 years of ribociclib to adjuvant NSAI in patients with hormone receptor–positive/-negative early breast cancer at risk of recurrence.

Corresponding Author: Peter A. Fasching, MD, University Hospital Erlangen, Comprehensive Cancer Centre Erlangen-EMN, Friedrich Alexander University Erlangen-Nuremberg, Universitätsstraße 21-23, D-91054 Erlangen, Germany (peter.fasching@uk-erlangen.de).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.